Literature DB >> 11040193

Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival.

F Lunel1, J F Cadranel, M Rosenheim, R Dorent, V Di-Martino, C Payan, C Fretz, J J Ghoussoub, B Bernard, B Dumont, M Perrin, I Gandjbachkh, J M Huraux, L Stuyver, P Opolon.   

Abstract

BACKGROUND & AIMS: We have observed a high prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in heart transplant recipients (HTRs). The aim of this study was to assess the epidemiology, natural history, and clinical and biological characteristics of viral hepatitis in HTRs.
METHODS: From 1983 to 1992, 874 patients underwent heart transplantation at the Pitié-Salpêtrière Hospital, Paris, France, 459 of whom qualified for analysis. A total of 140 patients had posttransplantation hepatitis B, C, or non-A-E. Sixty-nine patients developed HBV infection, 49 HCV infection, 11 HBV-HCV coinfection, and 11 non-A-E hepatitis.
RESULTS: HBV was transmitted nosocomially from patient to patient, most likely during endomyocardial biopsies. HCV was mainly transmitted through blood transfusions or the transplanted organ. Clinical and biological findings after 2 years of follow-up showed that 3 patients with an HBV genotype A precore mutant had severe or subfulminant hepatitis and that patients with HBV and HCV infection always progressed to chronicity. In general, patients had mild alanine aminotransferase level increases, a high level of viral replication, and few severe histologic lesions, except for patients infected by precore HBV mutants. Patients coinfected by HBV and HCV tended to have more severe liver lesions. The survival rate 5 years after transplantation in patients with viral hepatitis (HBV, 81%; HCV, 89%; HBV and HCV coinfection, 100%; non-A-E hepatitis, 73%) was similar to that in patients without liver test abnormalities (76%). The actuarial survival curve was also similar in patients with or without liver test abnormalities.
CONCLUSIONS: In our experience, histologic liver lesions do not progress rapidly in patients with post-heart transplant infection caused by HBV or HCV. HBV or HCV infection seems to have little impact on the 5-year survival rate of HTRs.

Entities:  

Mesh:

Year:  2000        PMID: 11040193     DOI: 10.1053/gast.2000.17951

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Cardiac Transplantation: Pre-transplant Infectious Diseases Evaluation and Post-transplant Prophylaxis.

Authors:  Susan Keay
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

2.  Effects of autoantibodies against beta(1)-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca(2+) currents.

Authors:  Kun Liu; Yu-Hua Liao; Zhao-Hui Wang; Shu-Li Li; Ming Wang; Ling-Lan Zeng; Ming Tang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

Review 3.  Management of patients with hepatitis B who require immunosuppressive therapy.

Authors:  Jessica P Hwang; Anna S-F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-11-19       Impact factor: 46.802

Review 4.  A concise review of hepatitis C in heart and lung transplantation.

Authors:  Edward Yc Kim; Hin Hin Ko; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2011-08       Impact factor: 3.522

5.  High prevalence of HCV infection among the general population in a rural area of central Italy.

Authors:  A Raffaele; M Valenti; M Iovenitti; A Matani; M L Bruno; E Altobelli; A D'Alessandro; R Barnabei; B Leonardis; G Taglieri
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 6.  Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation.

Authors:  Lucy Somerville; Karen Doucette
Journal:  Curr Infect Dis Rep       Date:  2018-05-22       Impact factor: 3.725

Review 7.  Viral prophylaxis in organ transplant patients.

Authors:  Michelle Slifkin; Shira Doron; David R Snydman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Authors:  Meghan E Sise; Ian A Strohbehn; Emily Bethea; Jenna L Gustafson; Raymond T Chung
Journal:  Curr Opin Organ Transplant       Date:  2019-06       Impact factor: 2.640

Review 9.  Treatment of hepatitis C in solid organ transplantation.

Authors:  Susan E Chan; Jonathan M Schwartz; Hugo R Rosen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon.

Authors:  Sara Belga; Karen Elizabeth Doucette
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.